Evaluation of droperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events

Evaluation of droperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events

Droperidol is a first-generation antipsychotic medication that has been used for various indications in the emergency department (ED); however, its use has been controversial due to reports of QT prolongation and the risk of torsades de pointes (TdP). The aim of the study is to evaluate the safety of droperidol administration in the ED.

A total of 327 administrations of droperidol were identified in 245 patients in the ED. The composite safety endpoint occurred in 30 (9.1%) administrations. None of these events were classified as “probable” or “definite” on the Naranjo adverse drug reaction probability scale. No episodes of TdP or serious ventricular arrhythmia were reported. Higher cumulative droperidol dose and creatinine clearance < 60 mL/min were associated with an increased odds of developing QTc prolongation (OR 1.27 [CI 1.04–1.56]) and (OR 1.01 [CI 1.0-1.02]), respectively.

Abdulmajeed M. Alshehri, Kaitlin E. Crowley, Kenneth E. Lupi, Christine S. Kim, Jeremy R. DeGrado & Kaylee Marino

https://bmcemergmed.biomedcentral.com/articles/10.1186/s12873-024-01158-9

BMC Emergency Medicine

18 december 2024

Fajar bagus W

PDF

English

Text